Clinical trial
Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or…
NCT00072228 · Daiichi Pharmaceuticals, Industry · Withdrawn
Key facts
| NCT number | NCT00072228 |
|---|---|
| Title | Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
| Official title | Phase I Study of Soblidotin and Gemcitabine in Patients With Locally Advanced or Metastatic Solid Tumors |
| Lead sponsor | Daiichi Pharmaceuticals, Industry |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Procedure |
| Interventions | gemcitabine, soblidotin, chemotherapy |
| First posted | Nov 6, 2003 |
| Last update posted | Jul 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: